Sort   by:  
 Page size 
Docetaxel is the standard first line therapy for hormone-refractory prostate cancer patients. Here we generated models of Docetaxel resistance in prostate cancer cells to study the molecular pathways that drive the acquisition of resistance to this therapy. We used microarrays to detail the global p...
ORGANISM(S): Homo sapiens 
MicroRNAs from lymphoma and leukemia cell lines with or without the 13q31 amplicon were quantitated using a custom microarray platform. 5ug total RNA from each line was labeled with cy3 and hybridized to a microarray that contains probes to 238 mouse and human mature microRNAs. Four data sets per ...
ORGANISM(S): Homo sapiens 
Gain-of-function mutations in NOTCH1 are common in T-cell lymphoblastic leukemias making this receptor a promising target for drugs such as gamma-secretase inhibitors, which block a proteolytic cleavage required for NOTCH1 activation. However, the enthusiasm for these therapies has been tempered by ...
ORGANISM(S): Homo sapiens 
To explore the mechanisms downstream of NOTCH1 and PTEN in the control of leukemia cell growth, we performed expression profiling on NOTCH1 induced and Pten-positive T-ALL tumor cells infected with constitutively active AKT (myristoylated-AKT). Constitutive activation of AKT rescues the transcriptio...
ORGANISM(S): Mus musculus 
To investigate the underlying mechanisms mediating resistance to NOTCH inhibition in Pten-null T-ALL tumor cells we performed gene expression profiling of isogenic Pten-positive and Pten-deleted leukemia lymphoblasts after acute treatment with DBZ in vivo. This analysis revealed that, while direct N...
ORGANISM(S): Mus musculus 
Hyper-activation of the PI 3-Kinase/ AKT pathway is a driving force of many cancers. Here we identify the AKT-inactivating phosphatase PHLPP1 as a prostate tumor suppressor. We show that Phlpp1-loss causes neoplasia and, upon partial Pten-loss, carcinoma in mouse prostate. This genetic setting initi...
ORGANISM(S): Mus musculus 
Sort   by:  
 Page size